Compare Johnson & Johnson (JNJ) vs TeraWulf Inc (WULF) Price & Performance

Johnson & Johnson (JNJ) trades at $249.58, down 1.37% today, amid a generally bullish technical outlook with strong moving average signals. The company reported robust Q2 2026 earnings, beating EPS estimates and raising full-year guidance, with revenue growth to $94.19B in 2025 and a net income margin of 21.48%. Recent news highlights strong institutional interest and positive analyst sentiment, though the stock faces pressure from MedTech segment misses despite overall strength.

The outlook for JNJ remains positive, supported by solid fundamentals, a consistent dividend history, and upward revised earnings guidance. Key risks include competitive pressures in pharmaceuticals, regulatory hurdles, and execution challenges in the MedTech division. With a consensus price target of $279.33, representing ~12% upside, the stock offers a compelling opportunity for long-term investors, balanced by sector-specific volatility and macroeconomic factors.

WULF trades at $18.86, up 3.85% today, but remains in a bearish technical trend. The company reported a net loss of -$661.42M in 2025 with a -611.46% net margin, though it secured a significant 20-year, $19B AI infrastructure deal with Anthropic. Analyst consensus is unanimously bullish with a $37.22 price target, citing long-term AI data center growth potential despite near-term profitability challenges.

The outlook hinges on successful execution of the Anthropic partnership to drive future revenue, but high valuation multiples and persistent losses pose substantial risks. Investors face volatility from operational cash burn and sector sentiment swings, requiring careful risk assessment against transformative AI infrastructure opportunities.